clearly significantP < 0.0001
Our results are consistent with those reported elsewhere, indicating reduced low back pain (VAS score) in 75% and reduced disease activity, which is clearly significant during the first 2–3 months and is maintained at ∼6 months according to the VAS score (−3.25, P < 0.0001), BASDAI (−1.86, P < 0.0001) and ASDAS (−1.0, P < 0.0001).